404 related articles for article (PubMed ID: 26924632)
21. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
22. The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery.
Wong QHY; Anderson RA
Curr Opin Endocrinol Diabetes Obes; 2018 Dec; 25(6):391-398. PubMed ID: 30299433
[TBL] [Abstract][Full Text] [Related]
23. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone.
Gleicher N; Weghofer A; Barad DH
Fertil Steril; 2009 May; 91(5):1700-6. PubMed ID: 18384775
[TBL] [Abstract][Full Text] [Related]
25. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
26. A 10-year follow up of reproductive function in women treated for childhood cancer.
Nielsen SN; Andersen AN; Schmidt KT; Rechnitzer C; Schmiegelow K; Bentzen JG; Larsen EC
Reprod Biomed Online; 2013 Aug; 27(2):192-200. PubMed ID: 23768622
[TBL] [Abstract][Full Text] [Related]
27. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.
Gleicher N; Weghofer A; Barad DH
Fertil Steril; 2010 Dec; 94(7):2824-7. PubMed ID: 20538269
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
[TBL] [Abstract][Full Text] [Related]
29. Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve.
von Wolff M; Roumet M; Stute P; Liebenthron J
Maturitas; 2020 Apr; 134():34-40. PubMed ID: 32143774
[TBL] [Abstract][Full Text] [Related]
30. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
[TBL] [Abstract][Full Text] [Related]
31. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.
Visser JA; Schipper I; Laven JS; Themmen AP
Nat Rev Endocrinol; 2012 Jan; 8(6):331-41. PubMed ID: 22231848
[TBL] [Abstract][Full Text] [Related]
32. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
[TBL] [Abstract][Full Text] [Related]
33. Diminished ovarian reserve in adolescent cancer survivors treated with heavy metal chemotherapy.
Pruett M; Williamson Lewis R; Klosky JL; Effinger KE; Meacham LR; Cherven B
Pediatr Blood Cancer; 2023 Aug; 70(8):e30448. PubMed ID: 37243931
[TBL] [Abstract][Full Text] [Related]
34. Age at menarche: a predictor of diminished ovarian function?
Weghofer A; Kim A; Barad DH; Gleicher N
Fertil Steril; 2013 Oct; 100(4):1039-43. PubMed ID: 23809497
[TBL] [Abstract][Full Text] [Related]
35. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
Mok CC; Chan PT; To CH
Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve.
van den Berg MH; Overbeek A; Lambalk CB; Kaspers GJL; Bresters D; van den Heuvel-Eibrink MM; Kremer LC; Loonen JJ; van der Pal HJ; Ronckers CM; Tissing WJE; Versluys AB; van der Heiden-van der Loo M; Heijboer AC; Hauptmann M; Twisk JWR; Laven JSE; Beerendonk CCM; van Leeuwen FE; van Dulmen-den Broeder E;
Hum Reprod; 2018 Aug; 33(8):1474-1488. PubMed ID: 29982673
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of combined FSH and AMH observations in infertile women.
Gleicher N; Kim A; Kushnir V; Weghofer A; Shohat-Tal A; Lazzaroni E; Lee HJ; Barad DH
J Clin Endocrinol Metab; 2013 May; 98(5):2136-45. PubMed ID: 23533225
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity.
Ben-Aharon I; Granot T; Meizner I; Hasky N; Tobar A; Rizel S; Yerushalmi R; Ben-Haroush A; Fisch B; Stemmer SM
Oncologist; 2015 Sep; 20(9):985-91. PubMed ID: 26099742
[TBL] [Abstract][Full Text] [Related]
39. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
Brougham MF; Crofton PM; Johnson EJ; Evans N; Anderson RA; Wallace WH
J Clin Endocrinol Metab; 2012 Jun; 97(6):2059-67. PubMed ID: 22472563
[TBL] [Abstract][Full Text] [Related]
40. Fertility preservation in childhood and adolescent female tumor survivors.
Filippi F; Meazza C; Somigliana E; Podda M; Dallagiovanna C; Massimino M; Raspagliesi F; Terenziani M
Fertil Steril; 2021 Oct; 116(4):1087-1095. PubMed ID: 34238574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
